Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk.
about
Oxidative stress, bone marrow failure, and genome instability in hematopoietic stem cellsMitophagy in hematopoietic stem cells: the case for explorationTherapy-related myeloid neoplasms - what have we learned so far?Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.Chemical metabolic inhibitors for the treatment of blood-borne cancersA module of human peripheral blood mononuclear cell transcriptional network containing primitive and differentiation markers is related to specific cardiovascular health variables.The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia.Transcription factor Oct1 is a somatic and cancer stem cell determinant.Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in miceMito-protective autophagy is impaired in erythroid cells of aged mtDNA-mutator mice.Granulocytes affect double-strand break repair assays in primary human lymphocytes.Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles.The RNA-binding protein QKI5 is a direct target of C/EBPα and delays macrophage differentiation.Using bioinformatic approaches to identify pathways targeted by human leukemogensAutophagy limits proliferation and glycolytic metabolism in acute myeloid leukemiaAutologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytesGEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia.Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AMLLoss of quiescence and impaired function of CD34(+)/CD38(low) cells one year following autologous stem cell transplantation.Therapy-related myelodysplasia and acute myeloid leukemiaTherapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer.Integration of hypoxic HIF-α signaling in blood cancers.JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia.The secrets of the bone marrow niche: Metabolic priming for AML.HSC senescence upon irradiation.Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation.Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis.Upregulated heme biosynthesis, an exploitable vulnerability in MYCN-driven leukemogenesis.Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair.Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AMLApplication of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.
P2860
Q26823605-B4296C08-D450-40E1-AFCA-ACCFA64372BBQ26865108-C27E9DEB-1692-40A8-B99D-FF61A314FAC1Q28071318-DC5395BD-0516-492A-915C-398DF529C086Q28294205-6CA96F61-4DC7-4B93-AA7A-5BB86A2CBDC2Q28822335-261A8414-769E-4BF7-9E71-63214F746E5FQ31159304-EE53C8D8-857D-49B6-82A6-3D4939446172Q33407572-C6CE87D5-5B56-4F80-923E-E9AE7EEF1EACQ33732606-C30679F5-1CC6-4262-9008-05B43BBBA070Q34473592-D816465B-6C38-4F5E-8329-C5F9C5BFE99DQ34737496-EA444163-5A49-4888-8319-291B26FA1EA7Q34802375-2074FB03-1ACB-41A8-B7F3-105FDABA9F3FQ35131489-D806F803-6454-4FEA-837A-FA2CC30ADF74Q35653085-638E53FD-7009-49E8-B6BE-77327A290577Q35917892-93632CA1-9F0A-480B-9337-4CE22AE89AC1Q36126146-A03A01F6-01AD-4313-869C-35636BF20F90Q36270307-B6EB5038-A997-4661-8D2F-F53509E9FAA0Q36282672-19297FF7-A146-424B-AAF7-9134260DE2E0Q36507980-97738416-A8CC-434C-B9B9-A79DCB00E85CQ36907852-8E4B9B98-F61B-4E17-B80F-5FF3DFC29B68Q37002149-6579C6E1-06E5-4433-BCB2-B736D0BA5D55Q37173297-3BEA7E72-43A0-44D5-A906-6D6B37AD1C93Q37377939-ABA54E32-81E3-4A71-86A3-B20726E94D81Q37402657-2753276E-05BD-4862-A734-4255B63EA930Q37548821-14F57298-F4FB-4CAA-B776-0A04124372CBQ38052129-011B19AD-003F-4904-AAFC-769FB047550EQ38407872-B8E3056B-C5C2-4FE7-861B-97C98A19437FQ38603374-E9DDBB4D-20D9-4A26-A590-D03430496752Q38769432-077B66F7-8C50-4494-9871-527E8295074AQ39190900-CEB742C9-239A-430A-98AE-4ACC206CCDDCQ39363565-C518F0B6-4DD5-42D6-8AD5-516C1B07A497Q39675064-31DC3702-F07A-46EB-B026-EB52A970DEFAQ40122866-12D059F8-0291-440E-917D-095185CF0DA9Q40716919-26E8BF0D-4DDA-4DF1-8034-8AB976E71BFBQ41252330-BB6224CE-B3FC-414E-B1B9-712324B1F051Q42195101-DACF23D6-51F2-4323-95D2-222E40B338BAQ42679067-95AD19F3-DF3B-4E29-A2DF-8F914AC9DA69Q42734570-6066779C-3F7A-449C-8DC6-53802D98D6F2Q44219414-9C6519A9-8267-40E1-8BC5-685AF67F1E7CQ51656403-FC51ADC0-286C-415A-AAF8-C09968369CF0
P2860
Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Altered hematopoietic cell gen ...... d identifies patients at risk.
@ast
Altered hematopoietic cell gen ...... d identifies patients at risk.
@en
type
label
Altered hematopoietic cell gen ...... d identifies patients at risk.
@ast
Altered hematopoietic cell gen ...... d identifies patients at risk.
@en
prefLabel
Altered hematopoietic cell gen ...... d identifies patients at risk.
@ast
Altered hematopoietic cell gen ...... d identifies patients at risk.
@en
P2093
P2860
P1433
P1476
Altered hematopoietic cell gen ...... d identifies patients at risk.
@en
P2093
Canlan Sun
Janelle Gyorffy
Jerald Radich
Jiangning Li
Karen Chang
Liton Francisco
Lue Ping Zhao
Melanie Sabado
P2860
P304
P356
10.1016/J.CCR.2011.09.011
P577
2011-11-01T00:00:00Z